The treatment regimen reduced the risk of developing distant metastases or death due to bladder cancer by 33%.

The phase 3 NIAGARA trial randomised 1,063 MIBC patients to receive Imfinzi plus neoadjuvant chemotherapy prior to bladder ...

AstraZeneca's Imfinzi perioperative regimen improved survival outcomes in muscle-invasive bladder cancer, with FDA Priority ...

WILMINGTON, Del.--(BUSINESS WIRE)--Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab), administered ...

Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s (AZN) IMFINZI, ...

AstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...

It remains to be seen if the data with Keytruda will be strong enough to supplant Imfinzi (durvalumab), which was approved for BTC by the FDA last year on the back of data from the TOPAZ-1 trial ...

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...

AstraZeneca, a global, science-led biopharmaceutical company, announced that its Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) as monotherapy for the treatment of ...

AstraZeneca AZN announced that CHMP has recommended approval for its blockbuster cancer drug Imfinzi (durvalumab) as a monotherapy for treating limited-stage small cell lung cancer (LS-SCLC ...

Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s (AZN) IMFINZI, administered perioperatively in combination with neoadjuvant ...